Humulin Nph

Humulin Nph is a subcutaneous injectable formulation of insulin human, supplied as a clear solution for subcutaneous administration. It is a recombinant human insulin product marketed in the European Union and prescribed by healthcare professionals for the management of blood glucose levels. The preparation contains insulin human as the sole active ingredient and is intended for use in patients with diabetes mellitus requiring basal insulin therapy.

Humulin Nph is indicated for the long‑acting basal insulin needs of adults and children with diabetes.

- Type 1 diabetes mellitus as part of a basal‑bolus insulin regimen. - Type 2 diabetes mellitus when basal insulin is required to achieve glycemic targets. - Adjunct therapy in patients whose blood glucose is not adequately controlled with oral antidiabetic agents alone. - Use during pregnancy or lactation only when the potential benefit outweighs potential risk, as determined by a clinician. - Transition from other basal insulin preparations may be performed under medical supervision, using appropriate dose conversion ratios.

Like insulin products, Humulin Nph may be associated with adverse reactions that vary in frequency and severity.

Common: - Mild hypoglycemia, especially if meals are delayed, carbohydrate intake is insufficient, or physical activity is increased. - Injection site reactions such as redness, swelling, itching, or a mild rash at the site of administration. - Lipodystrophy presenting as localized lipoatrophy (loss of fat) or lipohypertrophy (fat accumulation) at the injection area. - Transient weight gain due to fluid retention, often noticeable within the first few weeks of therapy. - Edema or peripheral swelling, particularly in the lower extremities, which may be apparent after higher doses.

Serious: - Severe hypoglycemia with neuroglycopenic symptoms such as confusion, seizures, loss of consciousness, or coma, requiring immediate treatment. - Allergic reactions ranging from mild urticaria and skin rash to severe anaphylaxis, which can be life‑threatening. - Insulin‑induced edema leading to rapid weight gain and peripheral edema, sometimes accompanied by shortness of breath.

Humulin Nph should be used with careful monitoring and consideration of patient‑specific factors to minimize risks.

- Assess renal and hepatic function before initiating therapy, as impairment may alter insulin clearance. - Adjust dose during periods of illness, stress, or changes in physical activity. - Monitor blood glucose frequently during dose titration and when switching from other insulin products. - Educate patients on proper injection technique and rotation of sites to prevent lipodystrophy. - Advise caution in pregnant or breastfeeding women; benefits must outweigh potential risks. - Store the product according to manufacturer instructions; avoid exposure to extreme temperatures which can degrade insulin potency.

Humulin Nph can interact with other medications, affecting glucose control or increasing the risk of adverse events.

Avoid: - Concomitant use of other rapid‑acting insulins without proper dose adjustment can lead to overlapping insulin action and result in severe hypoglycemia. - Beta‑blockers may mask the typical autonomic symptoms of hypoglycemia, making early detection and treatment more difficult for patients.

Use with caution: - Oral antidiabetic agents such as sulfonylureas or meglitinides can potentiate insulin’s glucose‑lowering effect, increasing the risk of hypoglycemia if doses are not adjusted. - Corticosteroids may increase insulin resistance and raise blood glucose levels, often necessitating an increase in insulin dose during therapy. - Diuretics, particularly thiazide‑type agents, can alter electrolyte balance and impair glucose tolerance, potentially affecting insulin requirements.